GREENFIELD, Ind. — Elanco Animal Health Inc. has announced that it has entered into an agreement with Bayer AG to acquire its animal health business in a transaction valued at $7.6 billion.
The transaction, which is subject to regulatory approval and other customary closing conditions, creates the second largest animal health leader while strengthening and accelerating the company's Innovation, Portfolio and Productivity (IPP) strategy, Elanco said.
The transaction will double Elanco's companion animal business, advancing the company's intentional portfolio mix transformation and creating a balance between its food animal and companion animal segments, the company noted, adding. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
